Prestige Consumer Healthcare Inc.(PBH)— Stock Profile, AI Score & Financials
Healthcare · NYSE · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
Prestige Consumer Healthcare Inc. (PBH) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PBH at 53.7/100 on a 32-signal composite quality model, placing it at rank #1,376 of 2,960 stocks — the top half of the AI-ranked universe. Areas of concern include revenue growth (23.3) and institutional flow (35.0), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q2 2026), Prestige Consumer Healthcare Inc. reports quarterly revenue of $265.7M, net income of $29.2M, free cash flow of $67.1M. Top institutional holders of PBH by reported 13-F value include BlackRock, ARIEL INVESTMENTS, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. PBH trades on the NYSE exchange and files with the SEC under CIK 1295947. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PBH daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Prestige Consumer Healthcare Inc. directly from SEC EDGAR.
AI Quality Score
53.7/100
AI Rank
#1,376
Revenue
$265.7M
Net Income
$29.2M
Free Cash Flow
$67.1M
PBH key financials by period
Prestige Consumer Healthcare Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2026
10-K
$1.1B
$190.3M
28.4%
FY 2025
10-K
$1.1B
$214.6M
29.6%
FY 2024
10-K
$1.1B
$209.3M
30.4%
FY 2023
10-K
$1.1B
$-82.3M
-2.0%
FY 2022
10-K
$1.1B
$205.4M
30.4%
FY 2021
10-K
$943.4M
$164.7M
31.5%
Institutions holding PBH
Institutional investors reporting a position in Prestige Consumer Healthcare Inc. on SEC Form 13F.
AI-extracted from the 10-Q filed 2026-08-06 — Q1 FY2027 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
PBH acquired Breathe Right and related brands for $1.045B on June 12, 2026, raising total revenue 6.5% YoY to $265.7M, though gross margin compressed 290 bps to 51.3% due to acquisition-related costs and inventory step-up amortization.
Biggest Revenue Drivers
North American OTC Healthcare$226.2M+6.4% YoY
Increases in Wellness/Sleep/Other (+165.7%), Gastrointestinal (+7.9%), Dermatologicals (+9.9%), and Cough/Cold/Allergy (+17.0%), partly offset by decreases in Women's Health (-5.1%) and Pain Relief (-3.8%).
International OTC Healthcare$39.5M+6.9% YoY
Increases in Wellness/Sleep/Other and Gastrointestinal, partly offset by decrease in Pain Relief.
Biggest Revenue Drivers
Total revenue: $265.7M+6.5% YoY
North American OTC Healthcare$226.2M+6.4% YoY
Increases in Wellness/Sleep/Other (+165.7%), Gastrointestinal (+7.9%), Dermatologicals (+9.9%), and Cough/Cold/Allergy (+17.0%), partly offset by decreases in Women's Health (-5.1%) and Pain Relief (-3.8%).
International OTC Healthcare$39.5M+6.9% YoY
Increases in Wellness/Sleep/Other and Gastrointestinal, partly offset by decrease in Pain Relief.
Largest Expense Items
Cost of sales (excluding depreciation)$126.5M+18.5% YoY
Increase driven by amortization of acquired inventory fair value step-up and costs related to improving and optimizing acquired Pillar5 facility.
Advertising and marketing$34.7M-0.8% YoY
Relatively flat versus prior year.
Margins: Gross margin contracted 290 basis points to 51.3% in Q1 FY2027 from 56.2% in Q1 FY2026, primarily driven by amortization of inventory fair value step-up from the OTC Wellness Business acquisition and costs associated with improving the acquired Pillar5 facility. Contribution margin (gross profit less advertising/marketing) declined 400 bps to 38.2%.
Watch Items from the Filing
Walmart represents 19% of Q1 FY2027 revenues (down from 22% YoY); Amazon 16% (up from 12% YoY). Two customers account for 35% of gross revenues, creating material customer concentration risk.
One privately owned pharmaceutical manufacturer supplies approximately 22% of gross revenues and accounted for a significant portion of that supplier's revenues; no long-term contract with certain other manufacturers creates supply disruption risk.
Sterile ophthalmic manufacturing capacity constraints persist: all sterile eye care manufacturing sites have undergone health authority inspections, with remediation activities potentially causing ongoing supply variability, reduced capacity, and production delays.
Total debt increased to $2.045B from $1.0B at March 31, 2026 due to $1.045B Term Loan for OTC Wellness Business acquisition and $95M drawn for LaCorium Health (July 1, 2026); subsequent $400M Senior Notes issuance redeemed $400M 2019 notes.
Pro forma Q1 FY2027 revenues would have been $297.5M (vs. actual $265.7M) and pro forma net income $36.4M (vs. actual $29.2M) had OTC Wellness Business been included from April 1, 2025; excludes anticipated synergies.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
